Fluoroquinolone resistance among Gram-positive cocci (Q34807455)

4 August 2017

1 reference

title

Fluoroquinolone resistance among Gram-positive cocci (English)

1 reference

4 August 2017

gram-positive bacteria

0 references

author name string

David C Hooper

series ordinal

1

1 reference

4 August 2017

1 September 2002

1 reference

Lancet Infectious Diseases

4 August 2017

1 reference

4 August 2017

2

1 reference

4 August 2017

9

1 reference

4 August 2017

530-538

1 reference

New uses for new and old quinolones and the challenge of resistance

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Trends in antimicrobial drug prescribing among office-based physicians in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Strategies for stemming the tide of antimicrobial resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Mechanisms of fluoroquinolone resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Increasing resistance of enterococci to ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Mutation frequencies and antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Low-level antibacterial resistance: a gateway to clinical resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Induction of SOS genes in Escherichia coli and mutagenesis in Salmonella typhimurium by fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Degradation of the fluoroquinolone enrofloxacin by the brown rot fungus Gloeophyllum striatum: identification of metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Complete Genome Sequence of Staphylococcus aureus EDCC 5398, a Clinical Isolate from Implant-Associated Bone Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory se

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

The mechanism of inhibition of topoisomerase IV by quinolone antibacterials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Bipolar localization of Bacillus subtilis topoisomerase IV, an enzyme required for chromosome segregation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Molecular properties of bacterial multidrug transporters

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Bacteria lacking a multidrug pump: a sensitive tool for drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

A mutation in the 5' untranslated region increases stability of norA mRNA, encoding a multidrug resistance transporter of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Expression of the multidrug resistance transporter NorA from Staphylococcus aureus is modified by a two-component regulatory system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Characterization of emeA, a NorA homolog and multidrug resistance efflux pump, in Enterococcus faecalis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

The population genetics of antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Antimicrobial use and antimicrobial resistance: a population perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Emergence of quinolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Ontario, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Epidemiologic typing of Staphylococcus aureus by DNA restriction fragment length polymorphisms of rRNA genes: elucidation of the clonal nature of a group of bacteriophage-nontypeable, ciprofloxacin-resistant, methicillin-susceptible S. aureus isolat

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Occurrence of quinolone resistance in Staphylococcus aureus from nosocomial infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Epidemiology of ciprofloxacin resistance among patients with methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY antimicrobial surveillance program, 1998-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

The epidemiology of resistance to ofloxacin and oxacillin among clinical coagulase-negative staphylococcal isolates: analysis of risk factors and strain types

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Epidemiology of the colonization of inpatients and outpatients with ciprofloxacin-resistant coagulase-negative staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Multiply antibiotic-resistant Staphylococcus epidermidis in patients, staff and environment--a one-week survey in a bone marrow transplant unit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

A randomized study comparing low dose ciprofloxacin and ofloxacin in the treatment of lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Use of oral ciprofloxacin in community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Levofloxacin failure in a patient with pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Emergence of extremely high penicillin and cefotaxime resistance and high-level levofloxacin resistance in clinical isolates of Streptococcus pneumoniae in Hungary

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Enterococcal superinfection in patients treated with ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Antimicrobial-resistant enterococcal isolates from fluoroquinolone-naive children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Antimicrobial susceptibility of Bacillus anthracis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Quinolone resistance from a transferable plasmid.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Is there a role for antibiotic cycling in the intensive care unit?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900369-9

7 January 2021

10.1016/S1473-3099(02)00369-9

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12206969